Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020
April 22, 2020 17:41 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 22, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2020 financial results on Monday, April 27, 2020 before market...
LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020
April 07, 2020 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the public...
LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM
March 19, 2020 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 19, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today provided an update on its ZynquistaTM (sotagliflozin) program in type 2 diabetes,...
LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME
March 13, 2020 08:05 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects in...
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
March 12, 2020 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
XERMELO® (telotristat ethyl) 2019 U.S. Net Sales Reached $31.0 Million THE WOODLANDS, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported...
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020
March 05, 2020 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 05, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March...
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
January 24, 2020 15:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in...
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
January 20, 2020 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be...
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
January 06, 2020 18:09 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
December 20, 2019 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in...